PER-052-04已完成未知
A MULTICENTER STUDY OF 24 WEEKS OF DURATION, RANDOMIZED, DOUBLE-BLIND AND WITH SIMILAR ASPECT DRUGS, TO COMPARE THE EFFECTIVENESS OF AVANDIA FOR PROLONGED RELEASE (8 MG ONCE PER DAY) AND AVANDIA OF IMMEDIATE RELEASE (8 MG ONCE A DAY ) IN SUBJECTS WITH DIABETES MELLITUS OF TYPE 2.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Subjects with a clinical diagnosis of type 2 diabetes mellitus according to the ADA.
- •Male or female adults who are between 18 and 75 years of age at the time of selection.
- •Subjects that give their informed consent to participate.
排除标准
- •Any clinically significant abnormality identified in the Screening Visit.
- •The use of any investigational drug within 30 days or 5 half-lives (whichever is longer) before administering the first dose of study medication
- •Anemia, defined by a hemoglobin concentration <11 g / dL for men or <10 g / dL for women.
- •The subject has a hemoglobinopathy.
研究者
相似试验
进行中（未招募）
不适用
Estudio de 24 semanas de duración, multicéntrico, abierto y comparativo de dos estrategias (insulina glargina frente a insulina premezclada) para el tratamiento de pacientes con diabetes de tipo 2 que han fracasado a los fármacos oralesA 24-week, open, multicenter, comparative study of 2 strategies (including insulin glargine versus premixed insulin) for the therapeutic management of patients with type 2 diabetes failing oral agents - GALAPAGOSDiabetes tipo 2 con fracaso a las intervenciones en el estilo de vida y a los fármacos oralesMedDRA version: 11Level: LLTClassification code 10063624Term: Diabetes melitus tipo II inadecuadamente controladaEUCTR2009-018172-33-ESSANOFI AVENTIS GROUPE870
进行中（未招募）
1 期
A 24-WEEK MULTICENTRE, RANDOMISED, DOUBLE BLIND, CONTROLLED, PARALLEL GROUP NON-INFERIORITY STUDY TO ASSESS THE EFFICACY AND SAFETY OF OLMESARTAN MEDOXOMIL VERSUS CANDESARTAN CILEXETIL IN PATIENTS WITH SYMPTOMATIC HEART FAILURE (NYHA II-IV) - OLMEBNPEUCTR2007-003060-22-FRDAIICHI SANKYO EUROPE GmbH400
尚未招募
不适用
A 96-WEEK, PROSPECTIVE, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF MASITINIB 4.5 MG/KG/DAY VERSUS PLACEBO IN THE TREATMENT OF PATIENTS WITH PRIMARY PROGRESSIVE OR RELAPSE-FREE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS-G35 Multiple sclerosisG35Multiple sclerosisPER-003-16AB Science,
进行中（未招募）
1 期
Combination treatment with dapagliflozin and exenatide to investigate the effect of weight loss in subjects with obesity compared to placebo.Obesity defined as body mass index (BMI) 30-45 kg/m2Obesity related metabolic disordersMedDRA version: 18.0Level: LLTClassification code 10029885Term: Obesity, unspecifiedSystem Organ Class: 100000004861EUCTR2014-003432-39-SEDept of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University
进行中（未招募）
不适用
Olpadronate intra venous in chronic low back painon-specific Chronic Low Back Pain persisting for at least 3 monthsMedDRA version: 18.1Level: LLTClassification code 10008837Term: Chronic back painSystem Organ Class: 100000004859EUCTR2015-004269-96-NLGador S.A.